There are 2789 resources available
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1206P - UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Presenter: Jair Bar
Session: ePoster Display
1358P - Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor
Presenter: Dae Ho Lee
Session: ePoster Display
1359TiP - RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study
Presenter: Daniel Morgensztern
Session: ePoster Display
1360TiP - First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Presenter: Suresh Ramalingam
Session: ePoster Display
1361TiP - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Presenter: Egbert F. Smit
Session: ePoster Display
1282P - Biology of immune resistance in oncogenic driven advanced non-small cell lung cancer (aNSCLC)
Presenter: Mihaela Aldea
Session: ePoster Display
1283P - Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features
Presenter: Fariba Tohidinezhad
Session: ePoster Display